ReviewThe World Allergy Organization journal2021
Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence.
Review in The World Allergy Organization journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.
- European Guideline (EuroGuiDerm) on atopic eczema: Living update.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Guideline
- Dupilumab Efficacy in Children with Atopic Dermatitis with Different Phenotypes and Endotypes: A Case Series.Advances in therapy · 2025Trial
- Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Trial
- Defining the Potential for Disease Modification in Atopic Dermatitis.American journal of clinical dermatology · 2026Review
- Real-World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis.Clinical and translational allergy · 2026Article
- Revisiting Atopy: The IgE-Dependent Amplification Loop as a Forgotten Driver of Atopic Dermatitis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Calcineurin Inhibitors in Atopic Dermatitis: Balancing Tradition with Emerging Therapeutics.Medical sciences (Basel, Switzerland) · 2026Review
- A Case for Anti-IgE Vaccination.Allergy · 2026Review
- Adjunctive Use of VGH4 for Moderate-to-Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Trial.Life (Basel, Switzerland) · 2026Article
- Combined effect of atopic dermatitis and chronic kidney disease on overall and cardiovascular disease mortality.Scientific reports · 2026Article
- Therapeutic advances in pruritus as a model of personalized medicine.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Secretome as a novel regenerative strategy for atopic dermatitis: a comprehensive review.Stem cell research & therapy · 2026Review
- Atopic Multimorbidity in Adults With a Focus on Sensitization Patterns and T Cell Activation.Clinical and translational allergy · 2025Article
- The Mechanisms of Immunoglobulin E Sensitizations in Atopic Dermatitis.Immunology and allergy clinics of North America · 2025Review
- Tertiary Lymphoid Organs at the Center Stage of Skin's Humoral Immunity.Immunological reviews · 2025Review
- Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches.Biomolecules & therapeutics · 2025Review
- BCL-2 Multi-Strain Probiotics for Immunomodulation In Vitro and In Vivo Alleviation of Atopic Dermatitis.Microorganisms · 2025Article
- Plasmapheresis as a Potential Generalizable Therapy for Myocardial Infarction.Rejuvenation research · 2025Review
- Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Biologics and JAK inhibitors.Annals of dermatology · 2025Article
- Updated insights into the molecular pathogenesis of canine atopic dermatitis.Veterinary dermatology · 2025Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin E (IgE) plays an essential role in many allergic diseases. This review highlights the role of IgE in atopic dermatitis (AD), a common, chronic, and complex skin inflammation, and the available therapeutic approaches that target IgE in AD. We examine the existing data showing the use of omalizumab, the only biologic anti-IgE therapy available in clinical use, plasma apheresis, and a combination of both therapeutic approaches for the treatment of AD. Existing data on the efficacy of omalizumab in AD are inconclusive. A limited number of randomised controlled studies, few uncontrolled prospective and retrospective reports, as well as multiple case series and case reports observed varying degrees of the efficacy of omalizumab in AD. Omalizumab displays a trend of higher efficacy in AD patients with low IgE levels compared with those with very high-to-extremely high serum IgE concentrations. Plasma apheresis and its combination with omalizumab show good efficacy, even in patients with unusually high serum IgE concentrations. Combining apheresis and anti-IgE treatment may serve as a comprehensive therapeutic approach for patients with elevated levels of IgE. Dedicated clinical studies with robust study designs are needed to establish the therapeutic efficacy of omalizumab in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.